Who bought stab stock?
STAB stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, Cambridge Investment Research Advisors Inc., UBS Group AG, BlackRock Inc., Dowling & Yahnke LLC, and Raymond James Financial Services Advisors Inc.. How do I buy shares of Statera BioPharma?
What is the ticker symbol for statera Biopharma?
Statera BioPharma trades on the NASDAQ under the ticker symbol "STAB." Who are Statera BioPharma's major shareholders? Statera BioPharma's stock is owned by many different retail and institutional investors.
Is stab stock up 115% on a Green Day?
Currently, STAB stock has appreciated more than 115% on an otherwise impressive green day in the market. A number of biotech stocks and other higher-risk equities are outperforming today, as various high-profile earnings reports roll in.
Is STAB a buy or sell?
Strong Buy(Delayed Data from NSDQ)Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is statera Biopharma a buy?
Finexy rates STAB stock as a strong buy based on 13 leading indicators (oscillators) and 11 lagging indicators (moving averages) that you can review here. This data suggests that Statera Biopharma, Inc.'s share price is likely to go up in the short-term.
What does Statera Biopharma do?
Statera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
Is stab stock going to go up?
Statera Biopharma Inc (NASDAQ:STAB) The 1 analysts offering 12-month price forecasts for Statera Biopharma Inc have a median target of 40.00, with a high estimate of 40.00 and a low estimate of 40.00. The median estimate represents a +16,806.17% increase from the last price of 0.24.
Who owns stab stock?
Institutional investors purchased a net $94.9 thousand shares of STAB during the quarter ended March 2019....Top 10 Owners of Statera Biopharma Inc.StockholderVirtu Financial BD LLCShares owned157,678Total value ($)36,581Shares bought / sold+126,715Total change+409.25%9 more columns
Where can I buy stab?
Shares of STAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How has Statera Biopharma's stock price performed in 2022?
Statera Biopharma's stock was trading at $2.30 at the start of the year. Since then, STAB shares have decreased by 89.4% and is now trading at $0.2...
What guidance has Statera Biopharma issued on next quarter's earnings?
Statera Biopharma issued an update on its FY 2021 earnings guidance on Tuesday, March, 15th. The company provided earnings per share guidance of fo...
Who are Statera Biopharma's key executives?
Statera Biopharma's management team includes the following people: Mr. Michael Kevin Handley , CEO, Pres & Chairman (Age 50, Pay $416.35k) Ms. C...
Who are some of Statera Biopharma's key competitors?
Some companies that are related to Statera Biopharma include Corbus Pharmaceuticals (CRBP) , Landos Biopharma (LABP) , Oragenics (OGEN) , Aegle...
What is Statera Biopharma's stock symbol?
Statera Biopharma trades on the NASDAQ under the ticker symbol "STAB."
Who are Statera Biopharma's major shareholders?
Statera Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Empery Asset Manageme...
Which institutional investors are selling Statera Biopharma stock?
STAB stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC.
Which institutional investors are buying Statera Biopharma stock?
STAB stock was acquired by a variety of institutional investors in the last quarter, including Empery Asset Management LP, Northern Trust Corp, Vir...
How do I buy shares of Statera Biopharma?
Shares of STAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
About Statera BioPharma
Statera BioPharma (NASDAQ:STAB) Frequently Asked Questions
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
Signals & Forecast
Statera BioPharma saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 153,600 shares, a drop of 35.7% from the January 15th total of 238,700 shares. Based on an average daily volume of 197,400 shares, the days-to-cover ratio is presently 0.8 days.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Wednesday, February 23, 2022, and so far it has risen 5.35%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Statera Biopharma, Inc.
Is Statera Biopharma, Inc. stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $0.67. With no support from accumulated volume below today's level the risk is increased, as a drop below the support at $0 may give a huge drop in the stock price.
Insiders are very positive buying more shares than they are selling in Statera Biopharma, Inc
Statera Biopharma, Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. We have upgraded our analysis conclusion for this stock since the last evaluation from a Strong Sell to a Sell candidate.
Golden Star Signal
In the last 42 trades there were 2.39 million shares bought and 10 thousand shares sold. The last trade was done 150 days ago by Markvicka Taunia who bough 100 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
47 Biggest Movers From Yesterday
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
32 Stocks Moving In Monday's Mid-Day Session
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share.
